Cencora Closes Public Offering of Senior Notes

By Chris Stiles • Monday, February 16 15:34 • Permanent Link

Cencora, Inc. (NYSE: COR) has announced the closing of its public offering of senior notes, with the company intending to use the net proceeds from the offering to repay amounts outstanding under its 364-day term credit agreement and for general corporate purposes.

The offering included: $500 million aggregate principal amount of 3.950% senior notes due February 13, 2029 $500 million aggregate principal amount of 4.250% senior notes due November 15, 2030 $500 million aggregate principal amount of 4.600% senior notes due February 13, 2033 $1.0 billion aggregate principal amount of 4.900% senior notes due February 13, 2036 * $500 million aggregate principal amount of 5.650% senior notes due February 13, 2056

Cencora's joint book-running managers for the offering were Citigroup Global Markets Inc., J.P. Morgan Securities LLC, BofA Securities, Inc., and Wells Fargo Securities, LLC.

Cencora is a leading global pharmaceutical solutions organization with more than $300 billion in annual revenue and is ranked #10 on the Fortune 500 and #18 on the Global Fortune 500.

The company has not made any forward-looking statements in this press release.

These figures indicate a significant amount of capital raised and the specific terms of the senior notes offering, with a diverse range of maturity dates and interest rates. Following these announcements, the company's shares moved -0.14%, and are now trading at a price of $354.85. For the full picture, make sure to review Cencora's 8-K report.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.